WAIKOLOA, Hawaii — Teprotumumab is in the last year of phase 3 clinical trials and could be a “breakthrough game changer” in treatment of Graves’ orbitopathy, Roger A. Dailey, MD, FACS, said at Hawaiian Eye 2019.
Considering autoantibodies stimulate cell surface antigens on orbital cells and produce the cascade of events that result in characteristic orbital thyroid eye disease inflammation, “it would be nice to have something that would block all those receptors competitively and keep the autoantibodies from turning on this whole series of inflammation,”
Uncategorized